Willow review

Willow publishes a real state list, transcribed here from its own FAQ, and names five partner pharmacies in its terms with street addresses and phone numbers — both rare on this roster. The four product pages each carry one clean per-month figure: $299 for compounded semaglutide, whether injection or tablet, and $399 for tirzepatide, either form. The problem is that the flat figure is not flat and the product pages do not say so. The comparison page asterisks the same numbers with pricing varies based on treatment plan and dosage; the FAQ says medication costs vary by dosage and prescription; and the terms authorize Willow to increase the subscription fee if the prescription changes, naming a dosage increase as an example. GLP-1 therapy is built around dose escalation and the site's own copy describes a gradual dose increase, so the $299 a buyer sees carries a change nobody flags where the price is printed. No dose-by-dose table appears on any of the ten pages read. One more disclosure gap worth naming: the comparison page carries a named physician's opinion recommending the more expensive of the two drugs, and it is the terms, on a different page, that disclose he is Willow's chief medical officer and holds an equity interest in the company. The clinical practice itself is never named, only defined; the privacy policy prints no address; and a platform fee applies if you use your own pharmacy, on a site whose FAQ answers no to additional fees. FDA warning-letter screen on Willow Health Services, Inc. by domain and by the Houston address in its terms: 0 of 0 matched, with the known-positive and known-negative controls both passing in the same run.